|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00314 SIPAI HEALTH
Nominal 
5.050 -0.040 (-0.786%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 4,565,434 | -3.113% | 4,712,107 | 4,119,478 | 3,473,930 | 2,699,647 |
| Cost of Sales | (4,179,001) | -2.755% | (4,297,409) | (3,782,126) | (3,190,481) | (2,512,787) |
| Gross Profit | 386,433 | -6.816% | 414,698 | 337,352 | 283,449 | 186,860 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (35,299) | 254.230% | (9,965) | (780,726) | (3,054,835) | (662,675) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (22,295) | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (187) | -54.612% | (412) | 331 | 137 | (65) | |
| Profit / (Loss) before Taxation | (360,641) | 46.801% | (245,666) | (1,368,442) | (3,747,678) | (1,040,850) | |
| Taxation | (1,191) | 14.409% | (1,041) | (3,322) | (825) | (1,179) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 38,096 | -- | (9,061) | 1,192 | 8,048 | (752) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (323,736) | 26.574% | (255,768) | (1,370,572) | (3,740,455) | (1,042,781) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (12,752) | -54.213% | (27,851) | (13,208) | (6,682) | 2,391 |
| Depreciation & Amortisation | 48,775 | -7.916% | 52,968 | 49,423 | 53,882 | 47,711 |
| Directors' Emoluments | -- | -- | 5,783 | 137,580 | 121,029 | 52,124 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -51.000 | 27.500% | -40.000 | -1,219.000 | -3,761.000 | -- |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.207) | (1.619) | (6.254) | -- |
| NBV per share ($) | 1.604 | -- | 2.126 | 2.407 | -- | -- |
| Remarks: | Real time quote last updated: 31/03/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -323,736 |
| %Change | 26.574% |
| EPS / (LPS) | RMB -0.510 |
| NBV Per Share (¥) | RMB 1.604 |